OncoMatch/Clinical Trials/NCT06764017
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Is NCT06764017 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CHiR-DEL for diffuse large b-cell lymphoma.
Treatment: CHiR-DEL — The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive
Histologically confirmed CD20-positive diffuse large B-cell lymphoma
Required: MYC overexpression (≥ 40% by immunohistochemistry)
Immunohistochemically confirmed positive expression of MYC (MYC ≥ 40% by immunohistochemistry)
Required: BCL2 overexpression (≥ 50% by immunohistochemistry)
Immunohistochemically confirmed positive expression of BCL2 (BCL2 ≥ 50% by immunohistochemistry)
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Lab requirements
Kidney function
creatinine < 2 times the upper limit of normal (ULN)
Liver function
ALT/AST < 2.5 ULN; total bilirubin < 2 ULN
Cardiac function
Cardiac, hepatic, and renal function: creatinine < 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase)/AST (aspartate aminotransferase) < 2.5 ULN; total bilirubin < 2 ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06764017 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD20?
Yes, CD20 positive is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC overexpression is a required biomarker for enrollment.
Does this trial require BCL2?
Yes, BCL2 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger and at least 70 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify